Form 4: Lineage Cell Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
George A. Samuel III, General Counsel and Secretary of Lineage Cell Therapeutics, was granted stock options to purchase 750,000 common shares.
Summary
- George A. Samuel III, the General Counsel and Secretary of Lineage Cell Therapeutics, was granted employee stock options on March 10, 2025.
- The options allow him to purchase 750,000 common shares at an exercise price of $0.53 per share.
- One quarter of the options will vest on March 10, 2026, with the remaining balance vesting in 36 monthly installments thereafter, contingent upon continuous employment.
- The options expire on March 10, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. However, it doesn't provide any concrete information about the company's performance or future prospects.
Positives
- The granting of stock options to a key executive aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies like Lineage Cell Therapeutics.
- Similar companies such as BioTime (now part of Lineage), Geron, and Athersys also utilize stock options to incentivize their leadership teams.
- The vesting schedule of one quarter after one year, followed by monthly vesting, is a common practice in the industry.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders if the options are exercised.
- The grant incentivizes the General Counsel and Secretary to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of the stock option grant. |
| 03/10/2026 | Date when 25% of the options vest. |
| 03/10/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.